PharmaMind Autonomous Lab Completes Full-Process Anti-Cancer Compound Discovery in 47 Days

PharmaMind Autonomous Lab Completes Full-Process Anti-Cancer Compound Discovery in 47 Days

London-based AI pharmaceutical company Verge Biotech announced today that its autonomous drug discovery platform PharmaMind independently completed the full discovery process for a candidate compound targeting EGFR-mutant non-small cell lung cancer—entirely without human intervention. From target identification to lead compound optimization, the process took just 47 days, representing an 85% reduction compared to traditional drug discovery timelines.

PharmaMind integrates three major modules—protein structure prediction, molecular dynamics simulation, and high-throughput virtual screening—unified through an autonomous reasoning engine that navigates chemical space. The system screened 26 million compounds in a virtual library, identifying 12 candidates, three of which demonstrated nanomolar-level inhibitory activity in vitro.

Raj Patel, Chief Scientific Officer at Verge Biotech, stated: "This isn't an assistive tool—it's a complete drug discovery agent. PharmaMind autonomously determined research strategies, adjusted screening parameters, and even switched to alternative targets when it discovered the initial target was undruggable."

The system is built on Verge's proprietary Prophet architecture, comprising a 12-billion-parameter scientific reasoning model and a specialized chemical language model. Unlike conventional AI-assisted drug discovery, PharmaMind requires no human-defined screening criteria or evaluation standards, relying instead on a built-in pharmacological knowledge graph for autonomous decision-making.

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has initiated discussions on a regulatory assessment framework for the system. Sarah Chen, Director of MHRA's Innovation Office, said: "Autonomous drug discovery raises entirely new regulatory questions. When AI independently completes the discovery process, clinical trial design and informed consent procedures need corresponding adjustments."

The pharmaceutical industry reacted cautiously to the breakthrough. James Miller, VP of AI R&D at Pfizer, noted: "A 47-day discovery timeline is impressive, but the path from candidate compound to approved drug still involves lengthy clinical trials. The critical question is whether PharmaMind's compounds will replicate their in vitro performance in humans."

Verge Biotech plans to initiate a Phase I clinical trial of the PharmaMind-001 compound in Q3 2028, enrolling 120 patients with advanced non-small cell lung cancer. If successful, this could become the first anti-cancer drug entirely discovered by AI to enter clinical trials.

Industry analysts predict PharmaMind's success will accelerate AI adoption across the pharmaceutical sector. McKinsey's latest report estimates that AI-driven autonomous drug discovery could reduce average new drug development costs from $2.6 billion to $800 million, and compress timelines from 10–15 years to 3–5 years.

However, concerns about the safety of autonomous AI drug discovery persist. MIT bioethics professor Laura Bennett warned: "When humans are removed from the drug discovery process, how do we ensure the AI doesn't optimize for compounds with low toxicity but unknown long-term side effects? Regulatory frameworks must keep pace with technological progress."